Immuron Limited (AU:IMC) has released an update.
Stephen Anastasiou has stepped down from his role as Non-Executive Director at Immuron Limited to concentrate on personal business restructuring and family time, after making significant contributions to the company including the launch of Travelan® in North America and aiding in its NASDAQ listing. Immuron, an Australian biopharmaceutical firm, specializes in orally delivered antibodies for infectious diseases, with its lead product Travelan® aimed at preventing travelers’ diarrhea.
For further insights into AU:IMC stock, check out TipRanks’ Stock Analysis page.
